Edward M. Arons, Ph.D.

Edward M. Arons, Ph.D., is a distinguished attorney at Weiss & Arons LLP, located in metropolitan New York. Mr. Arons serves clients throughout the United States and internationally. His legal practice encompasses:

• Patents
• Intellectual property (IP)
• IP-based business strategy development
• Investment and transactional due diligence
• Product clearance
• IP risk evaluation and management
• IP monetization
• Trademarks

Mr. Arons combines a robust scientific background with extensive legal experience to effectively meet the intellectual property demands of his technology clients. Over the years, he has represented a diverse range of entities, including international corporations, investors, and technology start-ups. 

By leveraging his technical and legal acumen, Mr. Arons adeptly extracts intellectual property assets from research and development settings, articulates their business significance to management and investors, and crafts patent portfolios that protect these assets and support fundraising efforts. His skill in presenting IP value propositions to potential investors is well-recognized.

Due to his extensive experience working with technology companies, Mr. Arons is frequently sought after by corporate acquirers and investors, including venture capital and private equity firms, to conduct due diligence investigations and provide strategic advice on product pipeline development, mergers and acquisitions IP risk, and licensing. He is frequently asked to offer legal opinions on the extent of rights owned by clients or their competitors.

Mr. Arons has played a pivotal role in counseling clients on technology-based transactions worth over $1B, many involving medical, diagnostic, and analytical laboratory instruments. His clients comprise a prominent international pharmaceutical company, a major U.S. biotech firm, pioneering telecommunications and material science companies, orthopedic and cardiology firms, as well as various consumer product businesses. Notably, his strategic patent portfolios for start-up medical device companies has resulted in over $200 million in funding.